Follow-up visit

[키워드] Academy age analysed antibody Antibody Response antibody titres B.1.351 B.1.617.2 Beta Beta variant breadth caused center Chinese collected communicable disease Communicable Disease Diagnosis COVID-19 Critical cross-reactive cytokine cytokine profile D614G D614G variant delta variant Delta variants detect detectable discharged disease disease severity ELISA ELISPOT enrolled enzyme evaluated Follow-up Follow-up visit follow-up visits foundation humoral humoral and T-cell response ICS IFN-γ IFNγ IgA IgG antibodies IgG antibody IgM IL-2 immune immune response In-vitro individual individuals Infection initial interferon interferon γ interleukin interleukin-2 intracellular cytokine staining longitudinal cohort study magnitude Medical Research Council Medical Sciences memory memory immune response memory T-cell response memory T-cell responses microneutralisation assay natural Necrosis neutralising Neutralising Antibodies neutralising antibody neutralising antibody response Neutralising antibody responses neutralising antibody titre neutralising antibody titres no difference not disrupted participant Patient patients patients with moderate PBMC PBMCs plasma plasma sample plasma samples Protein Receptor-binding domain recovered patient recovered patients recruited reduce reduced reducing reduction Reinfection remained retained robustness SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 nucleoprotein SARS-CoV-2 strain SARS-CoV-2 viral SARS-CoV-2-specific T-cell response Science severe disease spike Spike protein subset symptom severity Symptoms T-cell Response T-cell responses tested the interferon the receptor-binding domain the SARS-CoV-2 titre TNFα tumour necrosis factor Tumour Necrosis Factor α variant variants variants of concern Viral proteins viral strain viral strains Wuhan Wuhan, China
[DOI] 10.1016/S2666-5247(22)00036-2 PMC 바로가기 [Article Type] Article